Innovation1 Biotech Inc.

OTC: IVBT · Healthcare · Biotechnology

PublicHQ Somerville, NYCIK 0001629205Reports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ 22GM —SS 18

v0.1 · 25/100 weight · pillars only

↑ listing tenure, disclosure history · ↓ workforce scale, 3-yr revenue growth

Methodology →

Revenue TTM

$104.9k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$6.0M

Employees

Market cap

$4.5k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02023

Net income-$6.0M-$6.0M2023

Operating income-$1.4M-$1.4M2023

Total assets$76.0k$76.0k2023

Liabilities$3.5M$3.5M2023

Equity-$3.4M-$3.4M2023

Revenue trend

FY2018 – FY2023 · USD

$16.8k

FY18

$79.2k

FY19

$1.2k

FY20

$3.1k

FY21

FY22

FY23

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Innovation1 Biotech Inc. booked $0 in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Ingen Technologies, Inc.——Aridis Pharmaceuticals, Inc.——Radiko Holdings Corp——Life Stem Genetics Inc.——

Key facts

CEOFrancis Knuettel

SectorHealthcare

IndustryBiotechnology

HeadquartersSomerville, NY

ExchangeOTC: IVBT

Employees1

IPO date2017-09-22

Latest filings

10-Q2025-05-06 8-K2025-02-27 10-Q2025-01-27 10-K2024-01-17 8-K2023-12-13 8-K2023-11-07 8-K2023-10-16 10-Q2023-09-13

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.